Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/16/2026
- Wall St futures edge higher in countdown to Fed decision
- Oil slips as Saudi Arabia offers more crude via Oman; diesel near record high
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Global AI stocks fall as industry chiefs call for slowing development
- Stocks tend to rise after the Fed starts to hike
- U.S. Commerce Department to sell up to 9.9M GlobalFoundries shares
- Wall Street ends lower as oil spikes and the benchmark Treasury yield breaches 5%
- AI chip sell-off overblown: Zero GPU slowdown after Anthropic essay, analyst says
- Raymond James Downgrades Ascendis Pharma (ASND) to Outperform
- JPMorgan Downgrades Rapid7 (RPD) to Underweight
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Fulcrum Therapeutics Inc. (FULC) Misses Q1 EPS by 1c
May 9, 2022 7:07 AM EDTFulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q1 EPS of ($0.64), $0.01 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $2.59 million versus the consensus estimate of $3.94 million.
For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.
... More